Listing of Claims:

Claim 1 (currently amended) ~~Pharmaceutical compositions intended~~ A pharmaceutical composition for the treatment of urinary incontinence ~~characterized in that they contain~~ comprising oxybutynin as active ingredient, in combination or not with a moderated estrogen~~, in a mixture with~~ and a pharmaceutically acceptable excipient ~~or an inert vehicle, which is non-toxic,~~ intended for vaginal ~~route~~ or rectal ~~route~~ administration.

Claim 2 (currently amended) ~~Pharmaceutical compositions according to~~ A pharmaceutical composition of claim 1, ~~characterized in that~~ wherein oxybutynin is ~~chosen~~ selected from the group consisting of oxybutynin base, its addition salts with a mineral or organic acid and their epimers.

Claim 3 (currently amended) ~~Pharmaceutical compositions according to~~ A pharmaceutical composition of claim 1, ~~characterized in that~~ wherein the moderated estrogen is ~~chosen~~ selected from the group ~~formed by~~ consisting of estriol, estradiol and esters, ethers and mixed ethers of estriol ~~or~~ and estradiol.

Claim 4 (currently amended) ~~Pharmaceutical compositions according to~~ A pharmaceutical composition of claim 1, ~~characterized in that they are formulated in the form of~~ wherein it is selected from the form consisting of suppositories, ~~suppositories,~~ vaginal capsules, rectal capsules ~~or~~ and gels.

Claim 5 (currently amended) ~~Pharmaceutical compositions according to one of the preceeding claims, characterized in that they contain~~ A pharmaceutical composition of claim 1 wherein it contains from 1 to 25 mg of oxybutynin or its salts.

Claim 6 (currently amended) ~~Pharmaceutical compositions according to~~ A pharmaceutical composition of claim 5, ~~characterized in that they contain~~ wherein it contains from 5 to 15 mg of oxybutynin hydrochloride.

Claim 7 (currently amended) ~~Pharmaceutical compositions according to one of claims 1 to 6, characterized in that they contain~~ A pharmaceutical composition of claim 1 wherein it contains a dose of little resorbed moderated estrogen ranging from 0.01 to 5 mg per unit dose.

Claim 8 (currently amended) ~~Pharmaceutical compositions according to~~ A pharmaceutical composition of claim 7, ~~characterized in that~~ wherein the moderated estrogen is estriol at a dose of 0.1 to 2 mg.

Claim 9 (currently amended) ~~Pharmaceutical compositions according to~~ A pharmaceutical composition of claim 7 ~~or claim 8, characterized in that~~ wherein the unit dose of estriol ranges from 0.2 mg to 1 mg.

Claim 10 (currently amended) ~~Pharmaceutical compositions according to one of the preceding claims, characterized in that they also contain~~ A pharmaceutical composition of claim 1 wherein it contains one or more suspension agents.

Claim 11 (currently amended) ~~Pharmaceutical compositions according to~~ A pharmaceutical composition of claim 10, ~~characterized in that~~ wherein the suspension agent or agents are bioadhesive silicic acid derivatives ~~and in particular the colloidal silica marketed under the trade name Aerosil®~~.

Claim 12 (currently amended) ~~Pharmaceutical compositions according to one of the preceding claims, characterized in that~~ A pharmaceutical composition of claim 1 wherein the excipient is a fatty phase formed by semisynthetic glycerides.

Claim 13 (currently amended) ~~Pharmaceutical compositions according to~~ A pharmaceutical composition of claim 11, ~~characterized in that~~ wherein the semisynthetic glycerides are ~~those chosen from the products called~~ Witepsol® ~~and the products called~~ or Suppocire®.

Claim 14 (currently amended) ~~Pharmaceutical compositions according to one of the preceding claims characterized in that the formulations~~ A pharmaceutical composition of claim 1 which also ~~contain~~ contains one or more gelling agents.

Claim 15 (currently amended) ~~Pharmaceutical compositions according to~~ A pharmaceutical composition of claim 14, ~~characterized in that~~ wherein the gelling agent or agents are cellulose derivatives ~~and in particular alkylated and/or hydroxyalkylated cellulose derivatives~~.

Claim 16 (currently amended) ~~Pharmaceutical compositions according to~~ A pharmaceutical composition of claim 14, ~~in which~~ wherein the gelling agent is a carbomer.

Claim 17 (currently amended) ~~Pharmaceutical compositions according to~~ A pharmaceutical composition of claim 16, ~~in which~~ wherein the gelling agent is polycarbophil in acid form or in salified form.

Claim 18 (currently amended) ~~Pharmaceutical compositions according to~~ A pharmaceutical composition of claim 16 ~~or claim 17, in which~~ wherein the gelling agent is polycarbophil in the form of calcium salt.

Claim 19 (currently amended) ~~Pharmaceutical compositions according to one of the preceding claims, which bring about~~ A pharmaceutical composition of claim 1 having a sustained release of the active ingredients, spread over more than twenty four hours, ~~characterized in that~~ wherein the excipient is a fatty material in which the oxybutynin hydrochloride is placed in suspension.

Claim 20 (currently amended) ~~Pharmaceutical compositions according to one of the preceding claims~~ A pharmaceutical composition of claim 1, allowing T maxs of oxybutynin to be obtained ~~comprised~~ between approximately two hours and approximately sixteen hours ~~and preferably between six hours and twelve hours, characterized in that~~ wherein the excipient or the vehicle is ~~chosen~~ selected so that the speed of release is as long as possible.

Claim 21 (currently amended) ~~Pharmaceutical compositions according to one of the preceding claims, in which~~ A pharmaceutical composition of claim 1 wherein the excipient or the vehicle is ~~chosen~~ selected so that the administration of oxybutynin takes place once, or optionally twice, per twenty four hours.

Claim 22 (new) A method of treating urinary incontinency in humans comprising administrating to humans in need thereof an amount of a composition of claim 1 sufficient to treat urinary incontinency.